Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11900417 | 1.00 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4HCRTR1 | |
| SCHEMBL1672384 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1672390 | 0.76 | HCRTR1 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4HCRTR1 | |
| SCHEMBL1672046 | 0.75 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4HCRTR1 | |
| SCHEMBL13668658 | 0.73 | HTR3A (0.48) | — | |
| SCHEMBL1672473 | 0.73 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4HCRTR1 | |
| SCHEMBL1672461 | 0.73 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4HCRTR1 | |
| SCHEMBL1672179 | 0.73 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4HCRTR1 | |
| SCHEMBL1671974 | 0.73 | CHRNA7 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4HCRTR1 | |
| SCHEMBL1671076 | 0.72 | HCRTR1 (0.53) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| EP-2491034-B1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-18 | — | — | EP | disclosed |
| EP-2491034-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | CHRNB2 245/4885CHRNB4 262/4885CHRNA3 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.